APA (7th ed.) Citation

Leng, X., Leszczyński, P., Jeka, S., Liu, S., Liu, H., Miakisz, M., . . . Zeng, X. (2024, September). A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: Treatment period 2 analysis (week 24 to week 48). Arthritis Research & Therapy.

Chicago Style (17th ed.) Citation

Leng, Xiaomei, et al. "A Phase 3, Randomized, Double-blind, Active-controlled Clinical Trial to Compare BAT1806/BIIB800, a Tocilizumab Biosimilar, with Tocilizumab Reference Product in Participants with Moderate-to-severe Rheumatoid Arthritis with Inadequate Response to Methotrexate: Treatment Period 2 Analysis (week 24 to Week 48)." Arthritis Research & Therapy Sep. 2024.

MLA (9th ed.) Citation

Leng, Xiaomei, et al. "A Phase 3, Randomized, Double-blind, Active-controlled Clinical Trial to Compare BAT1806/BIIB800, a Tocilizumab Biosimilar, with Tocilizumab Reference Product in Participants with Moderate-to-severe Rheumatoid Arthritis with Inadequate Response to Methotrexate: Treatment Period 2 Analysis (week 24 to Week 48)." Arthritis Research & Therapy, Sep. 2024.